Literature DB >> 12733869

Structural biasing elements for in-cell histone deacetylase paralog selectivity.

Jason C Wong1, Roger Hong, Stuart L Schreiber.   

Abstract

We use the structural dissection of two 1,3-dioxanes with in-cell histone deacetylase (HDAC) paralog selectivity to identify key elements for selective HDAC inhibitors. We demonstrate that o-aminoanilides are inactive toward HDAC6 while apparently inhibiting deacetylases that act upon histone substrates. This finding has important clinical implications for the development of HDAC inhibitor-based treatments that do not interfere with microtubule dynamics associated with HDAC6. We also show that suberoylanilide hydroxamic acid (SAHA) alone is a nonparalog-selective HDAC inhibitor and that the 1,3-dioxane diversity appended to SAHA is essential for HDAC6 paralog selectivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12733869     DOI: 10.1021/ja0341440

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  27 in total

1.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs.

Authors:  Tatiana Akimova; Guanghui Ge; Tatiana Golovina; Tatiana Mikheeva; Liqing Wang; James L Riley; Wayne W Hancock
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 3.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

Review 4.  Isoform-selective histone deacetylase inhibitors.

Authors:  Anton V Bieliauskas; Mary Kay H Pflum
Journal:  Chem Soc Rev       Date:  2008-05-08       Impact factor: 54.564

5.  Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors.

Authors:  Arturo J Vegas; James E Bradner; Weiping Tang; Olivia M McPherson; Edward F Greenberg; Angela N Koehler; Stuart L Schreiber
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

6.  Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

Authors:  C T Chan; J Qi; W Smith; R Paranol; R Mazitschek; N West; R Reeves; G Chiosis; S L Schreiber; J E Bradner; R Paulmurugan; S S Gambhir
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

7.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Authors:  Teru Hideshima; Jun Qi; Ronald M Paranal; Weiping Tang; Edward Greenberg; Nathan West; Meaghan E Colling; Guillermina Estiu; Ralph Mazitschek; Jennifer A Perry; Hiroto Ohguchi; Francesca Cottini; Naoya Mimura; Güllü Görgün; Yu-Tzu Tai; Paul G Richardson; Ruben D Carrasco; Olaf Wiest; Stuart L Schreiber; Kenneth C Anderson; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

8.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

9.  Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.

Authors:  Chunping Xu; Elisabetta Soragni; C James Chou; David Herman; Heather L Plasterer; James R Rusche; Joel M Gottesfeld
Journal:  Chem Biol       Date:  2009-09-25

Review 10.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.